U.S. stock futures dropped on Monday following Friday’s mixed close. Futures of major benchmark indices were lower.This week, investors are eyeing earnings from UnitedHealth Group Inc. (NYSE:UNH) , General Motors Co. (NYSE:GM) , Microsoft Corp. (NASDAQ:MSFT) , Meta Platforms Inc. (NASDAQ:META) , Tesla Inc. (NASDAQ:TSLA) , Starbucks Corp. (NASDAQ:SBUX) , and others.The investors will also keep an eye on the Federal Open Market Committee’s decision on interest rates, slated to be announced on Wednesday.Meanwh ...

Market Overview - U.S. stock futures declined on Monday following a mixed close on Friday, with major benchmark indices showing lower futures [1] - Investors are focused on upcoming earnings reports from companies such as UnitedHealth Group, General Motors, Microsoft, Meta Platforms, Tesla, and Starbucks [1] - The Federal Open Market Committee's interest rate decision is anticipated on Wednesday [1] Treasury Yields - The yield on the 10-year Treasury bond is at 4.21%, while the two-year bond yield stands at 3.59% [2] - Market projections indicate a 97.2% likelihood that the Federal Reserve will keep interest rates unchanged in January [2] Index Performance - Dow Jones decreased by 0.12%, S&P 500 fell by 0.24%, Nasdaq 100 dropped by 0.44%, and Russell 2000 declined by 0.29% [3] - SPDR S&P 500 ETF Trust (SPY) was down 0.22% at $687.69, and Invesco QQQ Trust ETF (QQQ) declined 0.43% to $620.04 in premarket trading [3] Stocks in Focus - Baker Hughes Co. reported a 3.74% increase in premarket trading after posting adjusted earnings of 78 cents per share, exceeding estimates of 67 cents [7] - Sarepta Therapeutics Inc. saw a 6.72% rise after completing a trial commitment for its PMO therapies and releasing third-quarter results [7] - Nucor Corp. is projected to report quarterly earnings of $1.91 per share on revenue of $7.87 billion [7] - WR Berkley Corp. is expected to report earnings of $1.13 per share on revenue of $3.66 billion, with a weaker price trend according to Benzinga's Edge Stock Rankings [15] Analyst Insights - Mohamed El-Erian notes a "2025 Paradox" where financial markets remain resilient despite geopolitical tensions, with U.S. economic activity appearing robust [11] - El-Erian anticipates the Federal Reserve will maintain interest rates, with a focus on corporate earnings from tech giants and political issues affecting market stability [12][13] Upcoming Economic Data - Key economic reports to watch include durable-goods orders, consumer confidence data, and the Federal Reserve's interest rate decision [17]

DOUG INGRAM Chief Executive Officer Sarepta Therapeutics, Inc. (NASDAQ:SRPT) 44th Annual J.P. Morgan Healthcare Conference San Francisco, California JANUARY 12, 2026 MAX, age 10 Dosed with ELEVIDYS at age 5 ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 1 Forward-looking statements In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this presentation. Any statements that are not statements of histor ...

Financial Data and Key Metrics Changes - For Q4 2024, the company reported total revenues of $658.4 million, an increase of $261.6 million compared to $396.8 million in Q4 2023 [64] - Net product revenue for Q4 2024 was $638 million, growing 75% year-over-year, and full-year net product revenue was $1.8 billion, representing a 56% increase [14][64] - The company achieved a GAAP net income of $159 million for Q4 2024, compared to $45.7 million in Q4 2023, and a non-GAAP net income of $206 million, up from $86.6 million [67] Business Line Data and Key Metrics Changes - ELEVIDYS sales for Q4 2024 were $384.2 million, a 112% increase from the previous quarter, and total sales since approval exceeded $1 billion [15][28] - The PMO franchise generated $254 million in Q4 2024, growing approximately 9% compared to Q4 2023, with individual revenues of $137.6 million for EXONDYS 51, $40.2 million for VYONDYS 53, and $76.2 million for AMONDYS 45 [31][32] Market Data and Key Metrics Changes - The company noted that ELEVIDYS has only treated about 5% of the on-label addressable patient population, indicating significant growth potential ahead [33][114] - The PMO franchise continues to perform well, growing organically without price increases, reflecting an increase in patients served in the Duchenne community [30] Company Strategy and Development Direction - The company aims to build on the success of Project Moonshot, focusing on expanding its gene therapy pipeline and achieving multiple potential blockbuster siRNA launches by the end of the decade [9][13] - The strategic collaboration with Arrowhead is expected to diversify the company's future, adding a broad platform of siRNA programs across various therapeutic areas [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2025 net product revenue guidance of $2.9 billion to $3.1 billion, representing approximately 70% growth over 2024 [42] - The company anticipates continued growth quarter-over-quarter throughout 2025, driven by the strong performance of ELEVIDYS and the PMO franchise [81] Other Important Information - The company plans to transition to suspension manufacturing to improve cost of goods sold (COGS) and has several significant milestones expected in 2025 [20][21] - The company has approximately $1.5 billion in cash and investments as of December 31, 2024, and secured a $600 million revolving credit facility [72][73] Q&A Session Summary Question: What is the cadence of patient onboarding in Q1? - Management reiterated confidence in guidance for 2025, expecting growth quarter-over-quarter as the launch ramps up [80] Question: What is the prevalence of limb-girdle muscular dystrophy type 2E? - Management indicated that type 2E is an ultra-rare disease, with a 50-50 split between ambulatory and non-ambulatory patients [85][87] Question: Will the upcoming data for FSHD and DM1 be conclusive? - Management emphasized the importance of early data as proof of biology, with expectations for safety and efficacy signals [108][110] Question: What is the status of ELEVIDYS and PMO reinvestment? - Management noted early days for drawing conclusions on reinvestment but indicated some instances of reimbursement for both therapies [116] Question: What is the timeframe for the $500 million share repurchase program? - The program has an 18-month timeframe, with plans to be opportunistic in deploying capital as cash reserves are built back up [124]